New study checks how well dacomitinib works for advanced lung cancer in everyday practice
NCT ID NCT06321510
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at how patients with advanced EGFR-positive non-small cell lung cancer fared while taking dacomitinib in real-world settings in Taiwan. Researchers tracked 29 adults who took dacomitinib pills at home until their cancer stopped responding. The goal was to see how often doses were changed or stopped, and how long patients lived without their disease getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dacomitinib (a targeted therapy pill taken by mouth)
- What this could lead to
- If successful, this study could confirm that dacomitinib is a safe and effective first-line treatment for advanced EGFR-positive lung cancer in real-world settings.
- What could go wrong
- This is a small, observational study with only 29 participants, so results may not apply to all patients. It does not compare dacomitinib to other treatments, so its relative effectiveness is unclear.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tri-Service General Hospital
Taipei, 11490, R.O.C., Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Your Tumor's DNA might predict immunotherapy success
- Can a new PET tracer light up hidden cancers?
- Fellow veterans may hold the key to earlier lung cancer detection